Results 1 to 10 of about 39,846 (186)

Ethambutol optic neuropathy [PDF]

Frontiers in Neurology
Ethambutol is an antitubercular drug that is commonly used in the areas of the world that is endemic to tuberculosis. It is used in infections caused by Mycobacterium tuberculosis and some non-tuberculous infections caused by Mycobacterium species ...
Padmaja Sudhakar, Kishor Acharya, Tonse Ashwini Kini   +2 more
doaj   +2 more sources

Adverse Drug Reactions to a Daily Fixed-dose Combination Based Antituberculosis Treatment Regime in India’s National Tuberculosis Elimination Programme: A Prospective Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: In India, the daily weight-based, Fixed Dose Combination (FDC) Antituberculosis Treatment (ATT) regime under the National Tuberculosis Elimination Programme (NTEP) was introduced, replacing the previous intermittent regime with the ...
Kapil Mate, Gyanshankar Mishra, Radha Munje   +2 more
doaj   +1 more source

Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy

Indian Journal of Ophthalmology, 2021
Ethambutol use may lead to permanent vision loss by inducing a dose- and duration-dependent optic neuropathy. This has been of concern to ophthalmologists and physicians both; however, ethambutol continues to be used because of its anti-mycobacterial ...
Rohit Saxena, Digvijay Singh, Swati Phuljhele, V Kalaiselvan, Satya Karna, Rashmin Gandhi, Anupam Prakash, Rakesh Lodha, Anant Mohan, Vimla Menon, Rajeev Garg   +10 more
doaj   +1 more source

Should Sputum Smear Examination Be Carried Out at the End of the Intensive Phase and End of Treatment in Sputum Smear Negative Pulmonary TB Patients? [PDF]

, 2012
The Indian guidelines on following up sputum smear-negative Pulmonary tuberculosis (PTB) patients differ from the current World Health Organization (WHO) guidelines in that the former recommends two follow up sputum examinations (once at the end of ...
Adithya Cattamanchi, Anthony D. Harries, EV Elm, J Morrison, Ram Pal Vashist, Rony Zachariah, S Satyanarayana, Sanjay P. Zodpey, Shivani Chandra, Srinath Satyanaryana, Sumit Malhotra   +10 more
core   +20 more sources

The first-line antituberculosis drugs, and their fixed-dose combination induced abnormal sperm morphology and histological lesions in the testicular cells of male mice

Frontiers in Cell and Developmental Biology, 2022
Rifampicin (RIF), Isoniazid (INH), Ethambutol (EMB), Pyrazinamide (PZA), and/or their fixed-dose combination (FDC) are extensively prescribed in the cure of Tuberculosis (TB) globally.
Adekunle A. Bakare, Victoria Y. Moses, Charles T. Beckely, Toluwani I. Oluyemi, Gift O. Ogunfeitimi, Aduragbemi A. Adelaja, Glory T. Ayorinde, Adeyinka M. Gbadebo, Olukunle S. Fagbenro, Olusegun I. Ogunsuyi, Opeoluwa M. Ogunsuyi, Olusoji Mayowa Ige   +11 more
doaj   +1 more source

Is the Pharmacokinetics of First-Line Anti-TB Drugs a Cause of High Mortality Rates in TB Patients Admitted to the ICU? A Non-Compartmental Pharmacokinetic Analysis

Tropical Medicine and Infectious Disease, 2023
Background: Patients with tuberculosis (TB) may develop multi-organ failure and require admission to intensive care. In these cases, the mortality rates are as high as 78% and may be caused by suboptimal serum concentrations of first-line TB drugs.
Francisco Beraldi-Magalhaes, Suzanne L. Parker, Cristina Sanches, Leandro Sousa Garcia, Brenda Karoline Souza Carvalho, Amanda Araujo Costa, Mariana Millan Fachi, Marcus Vinicius de Liz, Alexandra Brito de Souza, Izabella Picinin Safe, Roberto Pontarolo, Steven Wallis, Jeffrey Lipman, Jason A. Roberts, Marcelo Cordeiro-Santos   +14 more
doaj   +1 more source

Ethambutol-Induced bilateral retrobulbar neuritis with cecocentral scotoma in cervical tuberculous lymphadenitis patient: A case report with estimated plasma level consideration

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2022
Ethambutol is considered to be safest first-line antitubercular drug, and patient acceptability is rather good in both intensive and continuation phase of the tuberculosis treatment with daily regimen.
Bijoy Kumar Panda, Medha Bargaje, Vaibhav R Suryawanshi, Sathiyanarayanan Lohidasan   +3 more
doaj   +1 more source

Evaluation of the Long-term Effect of Ethambutol Usage on the Retinal Nerve Fiber Layer Using Spectral-Domain Optical Coherence Tomography

Beyoglu Eye Journal, 2020
INTRODUCTION[|]The aim of this study was to use spectral-domain optical coherence tomography (SD-OCT) to evaluate the long-term effect of ethambutol on the optic nerve fiber layer.[¤]METHODS[|]Twenty eyes of 10 patients who had been treated with ...
Gul Varan, Leyla Hazar, Ahmet Sahin
doaj   +1 more source

mbtD and celA1 association with ethambutol resistance in Mycobacterium tuberculosis: A multiomics analysis

Frontiers in Cellular and Infection Microbiology, 2022
Ethambutol (EMB) is a first-line antituberculosis drug currently being used clinically to treat tuberculosis. Mutations in the embCAB operon are responsible for EMB resistance.
Zhuhua Wu, Qiuchan Tan, Chenchen Zhang, Yuchuan Zhao, Qinghua Liao, Meiling Yu, Liuyue Xu, Jiawen Wang, Hongdi Liang, Haicheng Li, Liang Chen, Xunxun Chen, Wenjing Wei   +12 more
doaj   +1 more source

Antimycobacterial Activities of an Edible Mushroom Extract and its Synergy with the Standard Antituberculous Drugs [PDF]

Journal of Clinical and Diagnostic Research, 2018
Introduction: Tuberculosis is a leading cause of death in most developing countries mainly due to drug resistance. Mushrooms are reservoirs of many unexplored active ingredients in relation to antimicrobial applications, giving us a scope to exploit it ...
Debasmita Chatterjee, Dipankar Halder, Urmita Chakraborty, Devarati Dutta, Satadal Das   +4 more
doaj   +1 more source